These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9284985)

  • 1. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults.
    Olsen OT; Larsen KR; Jacobsan L; Svendsen UG
    Allergy; 1997 Aug; 52(8):853-9. PubMed ID: 9284985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study.
    Bahçeciler NN; Işik U; Barlan IB; Başaran MM
    Pediatr Pulmonol; 2001 Jul; 32(1):49-55. PubMed ID: 11416876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Der p 1 and Der p 2 induce less severe late asthmatic responses than native Dermatophagoides pteronyssinus extract after a similar early asthmatic response.
    Van Der Veen MJ; Jansen HM; Aalberse RC; van der Zee JS
    Clin Exp Allergy; 2001 May; 31(5):705-14. PubMed ID: 11422129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan.
    Niu CK; Chen WY; Huang JL; Lue KH; Wang JY
    Respir Med; 2006 Aug; 100(8):1374-83. PubMed ID: 16403616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.
    Lue KH; Lin YH; Sun HL; Lu KH; Hsieh JC; Chou MC
    Pediatr Allergy Immunol; 2006 Sep; 17(6):408-15. PubMed ID: 16925685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial.
    Varney VA; Tabbah K; Mavroleon G; Frew AJ
    Clin Exp Allergy; 2003 Aug; 33(8):1076-82. PubMed ID: 12911781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.
    Bousquet J; Scheinmann P; Guinnepain MT; Perrin-Fayolle M; Sauvaget J; Tonnel AB; Pauli G; Caillaud D; Dubost R; Leynadier F; Vervloet D; Herman D; Galvain S; André C
    Allergy; 1999 Mar; 54(3):249-60. PubMed ID: 10321561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of house dust mite avoidance measures on Der p 1 concentrations and clinical condition of mild adult house dust mite-allergic asthmatic patients, using no inhaled steroids.
    Cloosterman SG; Schermer TR; Bijl-Hofland ID; Van Der Heide S; Brunekreef B; Van Den Elshout FJ; Van Herwaarden CL; Van Schayck CP
    Clin Exp Allergy; 1999 Oct; 29(10):1336-46. PubMed ID: 10520054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure chamber for allergen challenge. A placebo-controlled, double-blind trial in house-dust-mite asthma.
    Rønborg SM; Mosbech H; Poulsen LK
    Allergy; 1997 Aug; 52(8):821-8. PubMed ID: 9284981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of specific immunotherapy with house dust mite extract on the bronchial responsiveness of paediatric asthma patients.
    Gruber W; Eber E; Mileder P; Modl M; Weinhandl E; Zach MS
    Clin Exp Allergy; 1999 Feb; 29(2):176-81. PubMed ID: 10051720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy.
    Stelmach I; Sobocińska A; Majak P; Smejda K; Jerzyńska J; Stelmach W
    Ann Allergy Asthma Immunol; 2012 Oct; 109(4):274-8. PubMed ID: 23010234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients.
    Cloosterman SG; Bijl-Hofland ID; van Herwaarden CL; Akkermans RP; van Den Elshout FJ; Folgering HT; van Schayck CP
    Chest; 2001 May; 119(5):1306-15. PubMed ID: 11348933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of anti-allergic mattress encasings on house dust mite-induced early- and late-airway reactions in asthmatic patients. A double-blind, placebo-controlled study.
    Rijssenbeek-Nouwens LH; Oosting AJ; De Monchy JG; Bregman I; Postma DS; De Bruin-Weller MS
    Clin Exp Allergy; 2002 Jan; 32(1):117-25. PubMed ID: 12002728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.
    Maestrelli P; Zanolla L; Pozzan M; Fabbri LM;
    J Allergy Clin Immunol; 2004 Apr; 113(4):643-9. PubMed ID: 15100667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.